ORIGINAL ARTICLE

Varicella vaccination in England and Wales: cost-utility analysis

M Brisson, W J Edmunds

Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ, UK; Department of Economics, City University, London EC1V 3HD, UK

Correspondence to:
Correspondence to:
Dr W J Edmunds, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK;
jedmunds{at}hpa.org.uk

Aims: To assess the cost-effectiveness of varicella vaccination, taking into account its impact on zoster.

Methods: An age structured transmission dynamic model was used to predict the future incidence of varicella and zoster. Data from national and sentinel surveillance systems were used to estimate age specific physician consultation, hospitalisation, and mortality rates. Unit costs, taken from standard sources, were applied to the predicted health outcomes.

Results: In England and Wales, the annual burden of VZV related disease is substantial, with an estimated 651 000 cases of varicella and 189 000 cases of zoster, resulting in approximately 18 000 QALYs lost. The model predicts that although the overall burden of varicella will significantly be reduced following mass infant vaccination, these benefits will be offset by a significant rise in zoster morbidity. Under base case assumptions, infant vaccination is estimated to produce an overall loss of 54 000 discounted QALYs over 80 years and to result in a net cost from the health provider (NHS) and the societal perspectives. These results rest heavily on the impact of vaccination on zoster. Adolescent vaccination is estimated to cost approximately £18 000 per QALY gained from the NHS perspective.

Conclusion: Routine infant varicella vaccination is unlikely to be cost-effective and may produce an increase in overall morbidity. Adolescent vaccination is the safest and most cost-effective strategy, but has the least overall impact on varicella.

Keywords: economic evaluation; immunisation; varicella; zoster

Abbreviations: GP, general practitioner; QALY, quality adjusted life year; VZV, varicella zoster virus; VZIG, varicella zoster immunoglobulin

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Brisson, M., Edmunds, W. J. (2006). Impact of Model, Methodological, and Parameter Uncertainty in the Economic Analysis of Vaccination Programs. Med Decis Making 26: 434-446 [Abstract]  
• Goldman, G. S. (2005). Universal Varicella Vaccination: Efficacy Trends and Effect on Herpes Zoster. International Journal of Toxicology 24: 205-213 [Abstract] [Full Text]  
• Salisbury, D. M. (2005). Development Of Immunization Policy And Its Implementation In The United Kingdom. Health Aff (Millwood) 24: 744-754 [Abstract] [Full Text]  
• Griebsch, I., Coast, J., Brown, J. (2005). Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health. Pediatrics 115: e600-e614 [Abstract] [Full Text]